Related Experiment Videos
Peripartum cardiomyopathy. A review
S Ferrero1, B M Colombo, F Fenini
1Department of Obstetrics and Ginaecology, University of Genoa, Genoa, Italy. simoneferrero@libero.it
Minerva Ginecologica
|April 25, 2003
Summary
Peripartum cardiomyopathy (PPCM) is a rare pregnancy complication with uncertain causes. Treatment focuses on managing systolic dysfunction and preventing thrombosis, with improved outcomes due to advances in dilated cardiomyopathy therapies.
Area of Science:
- Cardiology
- Obstetrics
- Maternal-Fetal Medicine
Background:
- Peripartum cardiomyopathy (PPCM) is a rare form of heart failure.
- It affects women in late pregnancy or early postpartum.
- The exact cause of PPCM remains unclear.
Purpose of the Study:
- To review the etiology, epidemiology, diagnosis, clinical course, treatment, and prognosis of PPCM.
- To synthesize current understanding of this rare cardiac condition.
Main Methods:
- Literature review of medical publications from 1966 to March 2002.
- MEDLINE database search for relevant studies on PPCM.
Main Results:
- PPCM etiology is uncertain, with proposed causes including myocarditis, immune response, hemodynamic stress, and tocolysis.
- Risk factors include advanced maternal age, multiparity, African descent, twinning, and prolonged tocolysis.
- Standard heart failure treatments (digoxin, diuretics, hydralazine/nitrates, heparin) are used; ACE inhibitors/ARBs are avoided in pregnancy.
Conclusions:
- PPCM management involves standard heart failure therapies and anticoagulation.
- Immunosuppressive therapy's role is ambiguous.
- Advances in dilated cardiomyopathy treatment and cardiac transplantation improve patient quality of life and survival.